SecBot SecBot
8-K/A ·Filed Mar 19, 2026

CPRX

CATALYST PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed8mo ago SEC0001193125-26-114764
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor the May 18, 2026 trial start for developments in the FIRDAPSE patent litigation. A delay reduces near-term downside risk but prolongs uncertainty around generic competition.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.33
T+0 close · Mar 19, 2026 · via day close
Latest settled
+40.44%
T+60 · $31.36
Vs SPY
+26.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $22.33entry
  2. T+1 · 8mo ago +2.06%α +3.80% · $22.79
  3. T+5 · 8mo ago +8.60%α +10.81% · $24.25
  4. T+20 · 7mo ago +17.60%α +9.98% · $26.26
  5. T+60 · 5mo ago +40.44%α +26.10% · $31.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Catalyst Pharmaceuticals filed an amended 8-K to correct a scrivener's error in the signature date of a prior filing. The amendment confirms a court order delaying the bench trial with Hetero USA, Inc. over FIRDAPSE patent validity from March 23, 2026 to May 18, 2026. No other changes were made.

Key Facts

  • Amendment No. 1 to Form 8-K filed to correct a scrivener's error in the signature date of the original March 18, 2026 filing.
  • District Court for the District of New Jersey delayed the bench trial in the patent litigation with Hetero USA, Inc. from March 23, 2026 to May 18, 2026.
  • The litigation concerns the validity of Catalyst's Orange Book-listed patents for FIRDAPSE, which expire in 2032, 2034, and 2037.
  • No other changes were made to the original filing; the delay does not reflect a ruling on the merits of the case.

Financial Impact

No immediate financial impact disclosed. Trial delay extends uncertainty but avoids near-term risk of adverse ruling.

litigation riskpatent exclusivityrevenue risk

Risk Factors

  • Adverse ruling in the patent trial could invalidate key FIRDAPSE patents and open the door to generic competition.
  • Extended litigation increases legal expenses and delays resolution of market exclusivity.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K/A Filing (Primary)0001193125-26-114764
Document: 0001193125-26-114764-index-headers.html0001193125-26-114764
Document: 0001193125-26-114764-index.html0001193125-26-114764
Document: 0001193125-26-114764.txt0001193125-26-114764

Track record

16 reports on CPRX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
  2. Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
  3. Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
  4. Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
  5. Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
  6. Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
  7. Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
  8. Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
  9. May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
  10. May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026